Corrigendum to “Phase 1/2 trial of glasdegib in patients with primary or secondary myelofibrosis previously treated with ruxolitinib” [Leukemia Res. 79 (2019) 38–44]Aaron T. Gerds,Tetsuzo Tauchi,Ellen Ritchie,Michael Deininger,Catriona Jamieson,Ruben Mesa,Mark Heaney,Norio Komatsu,Hironobu Minami,Yun Su,Naveed Shaik,Xiaoxi Zhang,Christine DiRienzo,Mirjana Zeremski,Geoffrey Chan,Moshe TalpazLeukemia Research（2019）引用 0|浏览47暂无评分AI 理解论文溯源树样例生成溯源树，研究论文发展脉络Chat Paper正在生成论文摘要
